Zamrini Edward, McGwin Gerald, Roseman Jeffrey M
Department of Neurology, School of Medicine, University of Alabama at Birmingham, Birmingham, 35294, USA.
Neuroepidemiology. 2004 Jan-Apr;23(1-2):94-8. doi: 10.1159/000073981.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been associated with a decreased risk for Alzheimer's disease (AD).
To evaluate the association between statin use and AD adjusted for comorbid medical conditions.
A nested case-control study.
Patients at the Veterans Affairs Medical Center in Birmingham, Ala., USA with a new diagnosis of AD (cases) between 1997 and 2001 (n = 309) and age-matched non-AD controls (n = 3,088).
Odds ratio for association between AD and statin use.
Statin users had a 39% lower risk of AD relative to nonstatin users (odds ratio 0.61, 95% confidence interval 0.42-0.87). This association appeared to be modified by the presence of certain chronic medical conditions (i.e., hypertension, ischemic heart disease and cerebrovascular disease) in that the reduced risk was observed among those with these diseases, whereas no association was observed among those without any of these conditions.
In this study, following adjustment for confounding factors, a statistically significant inverse association between statin use and AD was observed. The results lend support to looking at AD outcomes in trials of statins to further evaluate their possible beneficial effects.
3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）与阿尔茨海默病（AD）风险降低相关。
评估在调整合并症后他汀类药物使用与AD之间的关联。
一项巢式病例对照研究。
美国阿拉巴马州伯明翰退伍军人事务医疗中心1997年至2001年间新诊断为AD的患者（病例组，n = 309）以及年龄匹配的非AD对照者（n = 3088）。
AD与他汀类药物使用之间关联的比值比。
与未使用他汀类药物者相比，使用他汀类药物者患AD的风险降低39%（比值比0.61，95%置信区间0.42 - 0.87）。这种关联似乎因某些慢性疾病（即高血压、缺血性心脏病和脑血管疾病）的存在而有所改变，即患有这些疾病的人群中观察到风险降低，而在没有这些疾病的人群中未观察到关联。
在本研究中，调整混杂因素后，观察到他汀类药物使用与AD之间存在统计学显著的负相关。这些结果支持在他汀类药物试验中观察AD结局，以进一步评估其可能的有益效果。
